-+ 0.00%
-+ 0.00%
-+ 0.00%

OXB Confirms Manufacturing And Supply Partnership With Aura Biosciences For Late-Stage Development And Manufacturing Activities Of Belzupacap Sarotalocan

Benzinga·11/17/2026 12:22:05
  • Partnership established earlier this year supports Aura’s Phase 3 virus-like drug conjugates (VDC) client programme and preparations for potential future commercial supply
  • Programme builds on OXB’s extensive track record in process characterisation, PPQ and commercial-scale manufacturing
  • Programme is supported from OXB’s FDA-approved commercial-scale facility in Durham, North Carolina
     

Oxford, UK – 17 November 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today confirm its manufacturing and supply partnership with Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers. OXB is supporting late-stage development and manufacturing activities for Aura’s lead virus-like drug conjugate candidate, belzupacap sarotalocan (bel-sar), as Aura advances the programme through Phase 3 development and prepares for potential future commercial supply. Aura recently announced the partnership and its manufacturing strategy in its Q3 corporate update.

Aura’s programme is being supported from OXB’s process and analytical development facility in Bedford, Massachusetts, and FDA-approved, commercial-scale viral vector manufacturing facility in Durham, North Carolina, which brings drug substance and fill and finish capabilities together on one site. OXB has initiated technical transfer in preparation for process performance qualification (PPQ) and commercial production. Together, these activities will support Aura’s manufacturing readiness for late-stage clinical development, potential future regulatory filings and commercialisation.

This partnership reflects OXB’s leading position in the space, drawing on more than 30 years of viral vector process development, analytical and GMP manufacturing experience into clinical and commercial stages.